The world's first prescription for a monoclonal antibody treatment for hepatitis D was issued at a hospital in Beijing, marking a milestone in global hepatitis care, Science and Technology Daily reported yesterday. Developed by a team from Tsinghua University and Beijing-based biopharma firm Huahui Health, Libevitug is the first monoclonal antibody ever approved for viral hepatitis worldwide.